United States Federal Circuit
Purdue Pharma. L.P. v. Epic Pharma, LLC, 2014-1294
In appeals arising from consolidated Hatch-Waxman proceedings involving the reformulated version of the pain reliever OxyContin, asserting a number of claims from multiple different patents against the defendants who have all filed all of whom have filed Abbreviated New Drug Applications (ANDAs) seeking to sell generic versions of OxyContin, the District Court's judgment finding all of the asserted patent claims invalid and dismissal of all remaining claims is affirmed where: 1) the District Court did not clearly err in reaching he district court did not clearly in its anticipation determination of invalidity; and 2) the remaining actions are barred by collateral estoppel.
Appellate Information
- Published 2016/02/01
Judges
- PROST
Court
- United States Federal Circuit